Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies. [electronic resource]
Producer: 20150224Description: 697-714 p. digitalISSN:- 1178-2005
- Administration, Inhalation
- Adrenergic beta-2 Receptor Agonists -- administration & dosage
- Aged
- Area Under Curve
- Benzoxazines -- administration & dosage
- Bronchodilator Agents -- administration & dosage
- Drug Administration Schedule
- Equipment Design
- Ethanolamines -- administration & dosage
- Female
- Forced Expiratory Volume
- Formoterol Fumarate
- Humans
- Lung -- drug effects
- Male
- Middle Aged
- Nebulizers and Vaporizers
- Predictive Value of Tests
- Pulmonary Disease, Chronic Obstructive -- diagnosis
- Recovery of Function
- Respiratory Function Tests
- Severity of Illness Index
- Surveys and Questionnaires
- Time Factors
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.